Literature DB >> 8672545

Expression of cytidine deaminase in human solid tumors and its regulation by 1 alpha,25-dihydroxyvitamin D3.

S Watanabe1, T Uchida.   

Abstract

We found that vitamin D3 up-regulates the expression of cytidine deaminase (CDD) gene in some human solid tumor cell lines as well as the monocytic leukemia cell lines. Two kinds of full length CDD cDNA were identified from human placenta: one has glutamine and the other one has lysine at codon 27. The expression was tested in various normal tissues and the cancer cell lines. Northern blot analysis demonstrated high levels of CDD mRNA in leukocytes and moderate levels in liver, kidney, placenta, spleen and lung. Expression of CDD in 20 human cancer cell lines was highly variable and not related to its expression in normal tissues. Treatment of the cell lines with 1 alpha,25-dihydroxyvitamin D3 resulted in up-regulation of CDD expression in some lines but not others. Three of five gastric carcinoma cell lines and five of eight colorectal cancer lines had increased levels of CDD mRNA following 24 h treatment with vitamin D3. Increased mRNA was detected in gastric cancer MKN 45 cells after 3 h of treatment with vitamin D3 and increased enzyme activity was measured after 24 to 48 h. But no combined effect of calcitriol with 9-cis retinoic acid was found. Our results demonstrate that CDD can be up-regulated by vitamin D3 in some solid tumor cell lines.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8672545     DOI: 10.1016/0167-4889(96)00024-9

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  10 in total

1.  Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours.

Authors:  Milena Gusella; Felice Pasini; Caterina Bolzonella; Silvia Meneghetti; Carmen Barile; Antonio Bononi; Silvia Toso; Daniela Menon; Giorgio Crepaldi; Yasmina Modena; Laura Stievano; Roberto Padrini
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

Review 2.  The Emerging Role of Cytidine Deaminase in Human Diseases: A New Opportunity for Therapy?

Authors:  Audrey Frances; Pierre Cordelier
Journal:  Mol Ther       Date:  2019-12-06       Impact factor: 11.454

3.  A rearrangement of the CDD gene at the 5' UTR produces two types of transcripts that contain a natural antisense region.

Authors:  H Jung-Ha; Y Lee; D Kim; B H Song
Journal:  Mol Biol Rep       Date:  1998-11       Impact factor: 2.316

4.  Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter.

Authors:  Sara M Fitzgerald; Rakesh K Goyal; William R A Osborne; Jennifer D Roy; John W Wilson; R E Ferrell
Journal:  Hum Genet       Date:  2006-01-31       Impact factor: 4.132

5.  Calcitriol enhances gemcitabine anti-tumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model system.

Authors:  Wei-Dong Yu; Yingyu Ma; Geraldine Flynn; Josephia R Muindi; Rui-Xian Kong; Donald L Trump; Candace S Johnson
Journal:  Cell Cycle       Date:  2010-08-17       Impact factor: 4.534

6.  Oral hypomethylating agents: beyond convenience in MDS.

Authors:  Elizabeth A Griffiths
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

7.  PCR-based methods for CDA K27Q and A70T genotyping: genotypes and alleles distribution in a central Italy population.

Authors:  Francesco M Carpi; Silvia Vincenzetti; Daniela Micozzi; Alberto Vita; Valerio Napolioni
Journal:  Mol Biol Rep       Date:  2009-11-26       Impact factor: 2.316

8.  Human cytidine deaminase: a biochemical characterization of its naturally occurring variants.

Authors:  Daniela Micozzi; Francesco Martino Carpi; Stefania Pucciarelli; Valeria Polzonetti; Paolo Polidori; Santiago Vilar; Brian Williams; Stefano Costanzi; Silvia Vincenzetti
Journal:  Int J Biol Macromol       Date:  2013-10-29       Impact factor: 6.953

9.  Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004).

Authors:  Masanori Toyoda; Tetsuo Ajiki; Yutaka Fujiwara; Hiroaki Nagano; Shogo Kobayashi; Daisuke Sakai; Etsuro Hatano; Masashi Kanai; Shoji Nakamori; Atsushi Miyamoto; Akihito Tsuji; Satoshi Kaihara; Hisashi Ikoma; Shigekazu Takemura; Hideyoshi Toyokawa; Hiroaki Terajima; Satoshi Morita; Tatsuya Ioka
Journal:  Cancer Chemother Pharmacol       Date:  2014-03-11       Impact factor: 3.333

10.  Robust Classification of Small-Molecule Mechanism of Action Using a Minimalist High-Content Microscopy Screen and Multidimensional Phenotypic Trajectory Analysis.

Authors:  Nathaniel R Twarog; Jonathan A Low; Duane G Currier; Greg Miller; Taosheng Chen; Anang A Shelat
Journal:  PLoS One       Date:  2016-02-17       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.